Functionalization of Alginate with Extracellular Matrix Peptides Enhances Viability and Function of Encapsulated Porcine Islets
- PMID: 32255552
- PMCID: PMC7598935
- DOI: 10.1002/adhm.202000102
Functionalization of Alginate with Extracellular Matrix Peptides Enhances Viability and Function of Encapsulated Porcine Islets
Abstract
Translation of transplanted alginate-encapsulated pancreatic islets to treat type 1 diabetes has been hindered by inconsistent long-term efficacy. This loss of graft function can be partially attributed to islet dysfunction associated with the destruction of extracellular matrix (ECM) interactions during the islet isolation process as well as immunosuppression-associated side effects. This study aims at recapitulating islet-ECM interactions by the direct functionalization of alginate with the ECM-derived peptides RGD, LRE, YIGSR, PDGEA, and PDSGR. Peptide functionalization is controlled in a concentration-dependent manner and its presentation is found to be homogeneous across the microcapsule environment. Preweaned porcine islets are encapsulated in peptide-functionalized alginate microcapsules, and those encapsulated in RGD-functionalized alginate displays enhanced viability and glucose-stimulated insulin release. Effects are RGD-specific and not observed with its scrambled control RDG nor with LRE, YIGSR, PDGEA, and PDSGR. This study supports the sustained presentation of ECM-derived peptides in helping to maintain health of encapsulated pancreatic islets and may aid in prolonging longevity of encapsulated islet grafts.
Keywords: alginate; cell encapsulation; encapsulated pancreatic islets; type 1 diabetes.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Conflict of interest statement
Conflict of interest
The authors declare no conflict of interest.
Figures




Similar articles
-
Extracellular matrix inclusion in immunoisolating alginate-based microcapsules promotes longevity, reduces fibrosis, and supports function of islet allografts in vivo.Acta Biomater. 2023 Mar 1;158:151-162. doi: 10.1016/j.actbio.2022.12.068. Epub 2023 Jan 5. Acta Biomater. 2023. PMID: 36610609
-
Extracellular matrix components supporting human islet function in alginate-based immunoprotective microcapsules for treatment of diabetes.J Biomed Mater Res A. 2016 Jul;104(7):1788-96. doi: 10.1002/jbm.a.35706. Epub 2016 Mar 22. J Biomed Mater Res A. 2016. PMID: 26990360
-
Inclusion of extracellular matrix molecules and necrostatin-1 in the intracapsular environment of alginate-based microcapsules synergistically protects pancreatic β cells against cytokine-induced inflammatory stress.Acta Biomater. 2022 Jul 1;146:434-449. doi: 10.1016/j.actbio.2022.04.042. Epub 2022 Apr 30. Acta Biomater. 2022. PMID: 35500812
-
Immunological Challenges Facing Translation of Alginate Encapsulated Porcine Islet Xenotransplantation to Human Clinical Trials.Methods Mol Biol. 2017;1479:305-333. doi: 10.1007/978-1-4939-6364-5_24. Methods Mol Biol. 2017. PMID: 27738946 Review.
-
Design of a bioartificial pancreas(+).J Investig Med. 2010 Oct;58(7):831-7. doi: 10.231/JIM.0b013e3181ed3807. J Investig Med. 2010. PMID: 20683347 Free PMC article.
Cited by
-
Rat Islet pECM Hydrogel-Based Microencapsulation: A Protective Niche for Xenotransplantation.Gels. 2025 Jul 2;11(7):517. doi: 10.3390/gels11070517. Gels. 2025. PMID: 40710679 Free PMC article.
-
Tailoring Therapeutic Responses via Engineering Microenvironments with a Novel Synthetic Fluid Gel.Adv Healthc Mater. 2021 Aug;10(16):e2100622. doi: 10.1002/adhm.202100622. Epub 2021 Jun 23. Adv Healthc Mater. 2021. PMID: 34160135 Free PMC article.
-
Developmentally-Inspired Biomimetic Culture Models to Produce Functional Islet-Like Cells From Pluripotent Precursors.Front Bioeng Biotechnol. 2020 Oct 7;8:583970. doi: 10.3389/fbioe.2020.583970. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 33117786 Free PMC article. Review.
-
Large-scale perfused tissues via synthetic 3D soft microfluidics.Nat Commun. 2023 Jan 12;14(1):193. doi: 10.1038/s41467-022-35619-1. Nat Commun. 2023. PMID: 36635264 Free PMC article.
-
Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead.Nat Rev Endocrinol. 2025 Jan;21(1):14-30. doi: 10.1038/s41574-024-01029-0. Epub 2024 Sep 3. Nat Rev Endocrinol. 2025. PMID: 39227741 Free PMC article. Review.
References
-
- de Vos P, Lazarjani HA, Poncelet D, Faas MM; Adv. Drug Deliv. Rev 2014, 68, 15. - PubMed
-
- Orive G, Hernandez RM, Gascon AR, Calafiore R, Chang TMS, de Vos P, Hortelano G, Hunkeler D, Lacik I, Shapiro AM, Pedraz JL; Nat. Med 2003, 9, 104. - PubMed
-
- Leijs M, Villafuertes E, Haeck J, Koevoet W, Fernandez-Gutierrez B, Hoogduijn M, Verhaar J, Bernsen M, van Buul G, van Osch G; Eur. Cell. Mater 2017, 33, 43. - PubMed
-
- Zhao X, Liu S, Yildirimer L, Zhao H, Ding R, Wang H, Cui W, Weitz D; Adv. Funct. Mater 2016, 26, 2809.